|
1
|
Colombo N, Creutzberg C, Amant F, Bosse T,
González-Martín A, Ledermann J, Marth C, Nout R, Querleu D, Mirza
MR, et al: ESMO-ESGO-ESTRO Endometrial Consensus Conference Working
Group: ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer:
Diagnosis, treatment and follow-up. Ann Oncol. 27:16–41. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Amant F, Moerman P, Neven P, Timmerman D,
Van Limbergen E and Vergote I: Endometrial cancer. Lancet.
366:491–505. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Gool IC, Eggink FA, Freeman-Mills L,
Stelloo E, Marchi E, de Bruyn M, Palles C, Nout RA, de Kroon CD,
Osse EM, et al: POLE proofreading mutations elicit an antitumor
immune response in endometrial cancer. Clin Cancer Res.
21:3347–3355. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Church DN, Stelloo E, Nout RA, Valtcheva
N, Depreeuw J, ter Haar N, Noske A, Amant F, Tomlinson IP, Wild PJ,
et al: Prognostic significance of POLE proofreading mutations in
endometrial cancer. J Natl Cancer Inst. 107:4022014.PubMed/NCBI
|
|
5
|
Plante M, Touhami O, Trinh XB, Renaud MC,
Sebastianelli A, Grondin K and Gregoire J: Sentinel node mapping
with indocyanine green and endoscopic near-infrared fluorescence
imaging in endometrial cancer. A pilot study and review of the
literature. Gynecol Oncol. 137:443–447. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stelloo E, Bosse T, Nout RA, MacKay HJ,
Church DN, Nijman HW, Leary A, Edmondson RJ, Powell ME, Crosbie EJ,
et al: Refining prognosis and identifying targetable pathways for
high-risk endometrial cancer; a TransPORTEC initiative. Mod Pathol.
28:836–844. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wilczynska A and Bushell M: The complexity
of miRNA-mediated repression. Cell Death Differ. 22:22–33. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan R, Zhi Q, Zhao H, Han Y, Gao L, Wang
B, Kou Z, Guo Z, He S, Xue X, et al: Upregulated expression of
miR-106a by DNA hypomethylation plays an oncogenic role in
hepatocellular carcinoma. Tumour Biol. 36:3093–3100. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yen CS, Su ZR, Lee YP, Liu IT and Yen CJ:
miR-106b promotes cancer progression in hepatitis B
virus-associated hepatocellular carcinoma. World J Gastroenterol.
22:5183–5192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zheng Z, Zhang Y, Zhang Z, Yang Y and Song
T: Effect of miR-106b on invasiveness of pituitary adenoma via
PTEN-PI3K/AKT. Med Sci Monit. 23:1277–1285. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. METHODS. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Billingsley CC, Cohn DE, Mutch DG,
Stephens JA, Suarez AA and Goodfellow PJ: Polymerase ε (POLE)
mutations in endometrial cancer: Clinical outcomes and implications
for Lynch syndrome testing. Cancer. 121:386–394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Schuler KM, Rambally BS, DiFurio MJ,
Sampey BP, Gehrig PA, Makowski L and Bae-Jump VL: Antiproliferative
and metabolic effects of metformin in a preoperative window
clinical trial for endometrial cancer. Cancer Med. 4:161–173. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mehnert JM, Panda A, Zhong H, Hirshfield
K, Damare S, Lane K, Sokol L, Stein MN, Rodriguez-Rodriquez L,
Kaufman HL, et al: Immune activation and response to pembrolizumab
in POLE-mutant endometrial cancer. J Clin Invest. 126:2334–2340.
2016. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aune D, DA Rosenblatt Navarro, Chan DS,
Vingeliene S, Abar L, Vieira AR, Greenwood DC, Bandera EV and Norat
T: Anthropometric factors and endometrial cancer risk: A systematic
review and dose-response meta-analysis of prospective studies. Ann
Oncol. 26:1635–1648. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Trabert B, Wentzensen N, Felix AS, Yang
HP, Sherman ME and Brinton LA: Metabolic syndrome and risk of
endometrial cancer in the United States: A study in the
SEER-medicare linked database. Cancer Epidemiol Biomarkers Prev.
24:261–267. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schnall-Levin M, Rissland OS, Johnston WK,
Perrimon N, Bartel DP and Berger B: Unusually effective microRNA
targeting within repeat-rich coding regions of mammalian mRNAs.
Genome Res. 21:1395–1403. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin S and Gregory RI: MicroRNA biogenesis
pathways in cancer. Nat Rev Cancer. 15:321–333. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jonas S and Izaurralde E: Towards a
molecular understanding of microRNA-mediated gene silencing. Nat
Rev Genet. 16:421–433. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang J, Li S, Li L, Li M, Guo C, Yao J
and Mi S: Exosome and exosomal microRNA: Trafficking, sorting, and
function. Genomics Proteomics Bioinformatics. 13:17–24. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Delay C, Mandemakers W and Hébert SS:
MicroRNAs in Alzheimer's disease. Neurobiol Dis. 46:285–290. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang R, Li Y, Hou Y, Yang Q, Chen S, Wang
X, Wang Z, Yang Y, Chen C, Wang Z, et al: The
PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal
transition in gemcitabine resistance hepatoma cells. Oncotarget.
6:7000–7010. 2015.PubMed/NCBI
|
